About Abeona Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://abeonatherapeutics.com/
Frequently Asked Questions
What is the 52-week range for ABEO?
The 52-week high is $7.65 and the 52-week low is $4.
What is the P/E ratio for ABEO?
The P/E ratio data is currently unavailable.
What is the dividend yield for ABEO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -41.69%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -226.20%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.79.
Analyst Recommendation Trends
Wall Street analyst consensus for ABEO over the last few months:
Latest ABEO News
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to,
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Abeona Therapeutics had a busy week with treatment network expansion, an FDA approval tied to a licensed therapy and fresh analyst coverage.
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.
ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Abeona Therapeutics Inc. (ABEO) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 11:30 AM EDTCompany ParticipantsVishwas Seshadri...
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Se
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified c
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-29 | Vasanthavada Madhav | -4,902 | $5.1556 | $25,273 |
| 2026-09-29 | O'Malley Brendan M. | -6,727 | $5.1556 | $34,682 |
| 2026-09-29 | Seshadri Vishwas | -19,608 | $5.1556 | $101,091 |
| 2026-09-29 | Vazzano Joseph Walter | -9,191 | $5.1556 | $47,385 |
| 2026-09-01 | Alvino Mark | -15,000 | $5.8644 | $87,966 |
| 2026-07-21 | Vazzano Joseph Walter | -1,478 | $6.53 | $9,651 |
| 2026-07-09 | Vasanthavada Madhav | -12,606 | $6.9637 | $87,784 |
| 2026-07-09 | O'Malley Brendan M. | -12,050 | $6.9637 | $83,913 |
| 2026-07-09 | Seshadri Vishwas | -67,971 | $6.9637 | $473,330 |
| 2026-07-09 | Vazzano Joseph Walter | -24,880 | $6.9637 | $173,257 |
| 2026-06-30 | Alland Leila | -11,000 | $5.917 | $65,087 |
| 2026-06-15 | Silverstein Christine Berni | -18,160 | $5.7101 | $103,695 |
| 2026-06-09 | Vasanthavada Madhav | -5,450 | $5.3042 | $28,908 |
| 2026-06-09 | O'Malley Brendan M. | -6,305 | $5.3042 | $33,443 |
| 2026-06-09 | Seshadri Vishwas | -31,916 | $5.3042 | $169,289 |
| 2026-06-09 | Vazzano Joseph Walter | -25,646 | $5.3922 | $138,288 |
| 2026-06-09 | Vazzano Joseph Walter | -13,421 | $5.3042 | $71,188 |
| 2026-06-08 | Vasanthavada Madhav | -4,170 | $5.4295 | $22,641 |
| 2026-06-08 | O'Malley Brendan M. | -4,826 | $5.4295 | $26,203 |
| 2026-06-08 | Seshadri Vishwas | -24,428 | $5.4295 | $132,632 |
| 2026-06-08 | Vazzano Joseph Walter | -10,271 | $5.4295 | $55,766 |
| 2026-05-26 | Alvino Mark | -500 | - | - |
| 2026-05-22 | Alvino Mark | -6,500 | $5.4558 | $35,463 |
| 2026-05-15 | Crombez Eric | -26,143 | $5.5325 | $144,636 |
| 2026-05-11 | Vasanthavada Madhav | -5,548 | $5.9613 | $33,073 |
| 2026-04-01 | Goldan Keith A. | +32,751 | - | - |
| 2026-03-31 | Seshadri Vishwas | -29,985 | $4.3849 | $131,481 |
| 2026-03-16 | Vazzano Joseph Walter | -785 | $4.76 | $3,737 |
| 2026-02-02 | Silverstein Christine Berni | -20,070 | $5.0906 | $102,168 |
| 2026-02-02 | Wuchterl Donald A. | -14,814 | $5.0906 | $75,412 |
| 2026-02-02 | Alland Leila | -18,065 | $5.0906 | $91,962 |
| 2026-02-02 | Crombez Eric | -16,284 | $5.0906 | $82,895 |
| 2026-02-02 | Alvino Mark | -2,000 | $5.0906 | $10,181 |
| 2026-01-26 | Zeiher Bernhardt G | +37,313 | - | - |
| 2026-01-26 | Wuchterl Donald A. | +37,313 | - | - |
| 2026-01-26 | Charles Faith L. | +37,313 | - | - |
| 2026-01-26 | Amoroso Michael | +37,313 | - | - |
| 2026-01-26 | Alland Leila | +37,313 | - | - |
| 2026-01-26 | Silverstein Christine Berni | +37,313 | - | - |
| 2026-01-26 | Crombez Eric | +37,313 | - | - |
| 2026-01-26 | Alvino Mark | +37,313 | - | - |
| 2026-01-22 | Vasanthavada Madhav | -12,610 | $5.2861 | $66,658 |
| 2026-01-22 | O'Malley Brendan M. | -13,578 | $5.3309 | $72,383 |
| 2026-01-22 | Seshadri Vishwas | -69,832 | $5.3309 | $372,267 |
| 2026-01-22 | Vazzano Joseph Walter | -18,666 | $5.3309 | $99,507 |
| 2026-01-21 | Alvino Mark | -13,500 | $5.2277 | $70,574 |
| 2026-01-20 | Vasanthavada Madhav | +76,621 | - | - |
| 2026-01-20 | O'Malley Brendan M. | +113,949 | - | - |
| 2026-01-20 | Seshadri Vishwas | +365,422 | - | - |
| 2026-01-20 | Vazzano Joseph Walter | +133,595 | - | - |
| 2025-12-29 | Seshadri Vishwas | -25,000 | $5.3096 | $132,740 |
| 2025-11-13 | Alvino Mark | -15,000 | $4.7445 | $71,168 |
| 2025-10-16 | Seshadri Vishwas | -249 | $5.485 | $1,366 |